[Pefloxacin: clinical experience].
Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1). The following bacteria were isolated: P. aeruginosa: 11; Enterobacteriaceae: 10; Acinetobacter: 3; Staphylococci: 3 (including 2 methicillin-resistant strains), and Streptococcus faecalis: 2. Pefloxacin was given in a daily dosage of 800 mg in 20 patients and 1 200 to 1 600 mg in 7. All pathogens proved susceptible, in varying degrees. 21 patients recovered. Three incomplete results and three failures were observed. No significant side effects were recorded except for development of three mucosal candidiasis and two transient rashes. The authors put special emphasis on the value of pefloxacin in bone and meningeal infections.
D000151:Acinetobacter Infections / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D013293:Enterococcus faecalis; D005260:Female; D006801:Humans; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D008875:Middle Aged; D009643:Norfloxacin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010000:Osteitis / Q000188:drug therapy; D015366:Pefloxacin; D011552:Pseudomonas Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D015366:Pefloxacin; D009643:Norfloxacin
La péfloxacine: expérience clinique.